IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC). Wakelee, H. A., Altorki, N. K., Zhou, C., Csoszi, T., Vynnychenko, I. O., Goloborodko, O., Luft, A., Akopov, A., Martinez-Marti, A., Kenmotsu, H., Chen, Y., Chella, A., Sugawara, S., Gitlitz, B. J., Bennett, E., Wu, F., Yi, J., Deng, Y., McCleland, M., Felip, E. LIPPINCOTT WILLIAMS & WILKINS. 2021

View details for DOI 10.1200/JCO.2021.39.15_suppl.8500

View details for Web of Science ID 000708120604214